Listen on the go
    • Faculty & Disclosures
    Prof. John Mascarenhas

    Icahn School of Medicine at Mount Sinai
    New York, NY, USA

    John Mascarenhas is a professor of medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, USA, a member of the Tisch Cancer Institute, the director of the Adult Leukemia Program and leader of clinical research within the Myeloproliferative Disorders Research Program at ISMMS. read more

    As a clinical investigator in malignant haematology with a focus on translational research in myeloproliferative neoplasms (MPN), Prof. Mascarenhas is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Research Program at ISMMS. Prof. Mascarenhas is also the principal investigator (PI) of the clinical trials project within the National Cancer Institute sponsored by the Myeloproliferative Neoplasm Research Consortium. He has served as a PI or study chair of multiple investigator-initiated and industry-sponsored early- and late-phase clinical trials evaluating innovative approaches to the treatment of MPN and secondary leukaemia.

    Prof. John Mascarenhas discloses Advisory board or panel fees from AbbVie, Bristol Myers Squibb, Celgene, CTI BioPharma, Galecto Biotech, Geron Corporation, GlaxoSmithKline, Imago BioSciences, Inc., Incyte Corporation, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Pfizer, PharmaEssentia and Sierra Oncology. Grants/research support from AbbVie, Bristol Myers Squibb, Geron Corporation, Incyte Corporation, Kartos Therapeutics, Novartis and PharmaEssentia.
    Dr Raajit Rampal

    Memorial Sloan Kettering Cancer Center
    New York, NY, USA

    Raajit Rampal is a haematologic oncologist and associate member at the Memorial Sloan Kettering Cancer Center, and clinical director of the leukaemia service, based in New York, NY, USA. read more

    Dr Rampal is a physician-scientist with an active laboratory, and leads the clinical myeloproliferative neoplasms (MPN) programme at the Memorial Sloan Kettering Cancer Center. He received his MD and PhD at Stony Brook University, New York and completed his haematology/oncology fellowship at the Memorial Sloan Kettering Cancer Center, with post-doctoral training in the lab of Ross Levine. The focus of Dr Rampal’s research has been to utilize genetic insights from primary patient samples to elucidate mechanisms of pathogenesis in acute myeloid leukaemia and the Philadelphia chromosome-negative MPN, and to develop novel therapeutic strategies for these diseases.

    Dr Raajit Rampal discloses Advisory board or panel fees from AbbVie, Galecto Biotech, GlaxoSmithKline, Incyte Corporation, Kartos Therapeutics, Karyopharm Therapeutics, PharmaEssentia and SDP Pharma. Consultancy fees from Bristol Myers Squibb/Celgene, CTI BioPharma, MorphoSys, Servier, Stemline Therapeutics Inc. and Zentalis Pharmaceuticals. Grants/research support from Constellation Pharmaceuticals, Ryvu Therapeutics, Stemline Therapeutics Inc. and Zentalis Pharmaceuticals.
    Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    CORRECT!
    Next question
    touchHAEMATOLOGY touchHAEMATOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Haematological Malignancies

    EU Partner

    An Introduction to Haematological Malignancies

    In recent years, advances in our understanding of the pathological mechanisms underlying haematological malignancies have led to improved outcomes. Several novel drug classes are now emerging, including chimeric antigen receptor (CAR) T-cell therapy, molecular targeted therapies, bispecific T-cell engaging antibodies, CD47 blockade therapy and antibody-drug conjugates. Many challenges remain, however, including how best to combine agents and determining where new therapies fit into the treatment paradigm.

    Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.”

    Our supporting partners do not constitute an endorsement of the content on this page.

    Haematological Malignancies Content

    Myeloproliferative Disorders, Haematological Malignancies, Rare Diseases
    Watch Time: 38 mins
    touchIN CONVERSATION
    Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic
    CE/CME ACCREDITED Dr Raajit Rampal, Prof. John Mascarenhas

    Two haematologic oncologists discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.

    Learning objectives
    Learning Objectives
    • Discuss considerations for selecting an appropriate JAK inhibitor in the first-line treatment of myelofibrosis
    • Plan strategies for managing side effects associated with JAK inhibition in patients with myelofibrosis
    • Evaluate management approaches following lack of treatment success with first-line JAK inhibitor treatment in patients with myelofibrosis
    Leukaemia, Haematological Malignancies
    Developed by Touch
    Mark Levis, EHA 2023: MORPHO trial of gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia
    Watch Time: 6 mins

    BMT-CTN1506 (“MORPHO”) was an international phase III trial investigating the use of post-haematopoietic cell transplantation maintenance with the FLT3 inhibitor, gilteritinib, in patients with FLT3-ITD acute myeloid leukaemia. The aims and findings of the trial, as well as questions that remain to be answered, are discussed in this touchHAEMATOLOGY interview with Dr Mark Levis (Sidney […]

    Leukaemia, Haematological Malignancies
    Developed by Touch
    Jorge Cortes, EHA 2023: The use of quizarpenib in patients with acute myeloid leukaemia
    Watch Time: 6 mins

    We caught up with Prof Jorge Cortes (Georgia Cancer Center, Augusta University, GA, USA) to discuss his highlights from the recent EHA 2023 Congress, including two clinical trials that investigated the use of quizarpenib in patients with acute myeloid leukaemia. Abstracts discussed: Abstract S130: ‘Preliminary Results of QUIWI: A Double Blinded, Randomized Clinical Trial Comparing […]

    Myeloproliferative Disorders, Haematological Malignancies
    Developed by Touch
    John Mascarenhas, EHA 2023: Phase II MANIFEST trial: Pelabresib combined with ruxolitinib for patients with myelofibrosis
    Watch Time: 6 mins

    The phase II MANIFEST trial (NCT02158858) investigated the use of pelabresib combined with ruxolitinib for patients with myelofibrosis who are JAK inhibitor treatment-naïve. We caught up with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA), one of our valued Editorial Board members, to discuss the latest durability of response and safety results […]

    Myeloproliferative Disorders, Haematological Malignancies
    Developed by Touch
    John Mascarenhas, EHA 2023: Overview and limitations of current therapeutic options for myelofibrosis
    Watch Time: 5 mins

    Myelofibrosis is a complex haematological malignancy for which the current first-line treatment is Janus kinase inhibitors. touchHAEMATOLOGY caught up with one of our valued Editorial Board members, Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA) to discuss the current therapeutic options for myelofibrosis and their limitations. The abstract entitled ‘UPDATED DURABILITY […]

    Haematological Malignancies
    Developed by Touch
    Johan de Munter, EBMT 2023: Highlights from the Nurses Group Keynote Lecture
    Watch Time: 2 mins

    President of the European Oncology Nursing Society, Johan de Munter, discusses the key take-home messages from his Nurses Group Keynote Lecture at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting, 23-26 April 2023. Questions: Please summarise the key points from your Nurses Group Keynote Lecture presented at the EBMT conference 2023 (00:18) […]

    Myeloproliferative Disorders, Haematological Malignancies
    Developed by Touch
    Marina Kremyanskaya, EHA 2023: Findings of the REVIVE study of rusfertide in polycythaemia vera
    Watch Time: 4 mins

    The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. touchHAEMATOLOGY caught up with Dr Marina Kremyanskaya (Icahn School of Medicine at Mount Sinai, NY, USA) to discuss the main findings of the REVIVE study and the […]

    Myeloproliferative Disorders, Haematological Malignancies
    Developed by Touch
    Marina Kremyanskaya, EHA 2023: The REVIVE study of rusfertide in polycythaemia vera – aims and methodology
    Watch Time: 4 mins

    The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. The unmet needs in the treatment of polycythaemia vera and the aims, rationale and methodology of the REVIVE study are discussed in this touchHAEMATOLOGY interview with Dr […]

    Haematological Malignancies, Multiple Myeloma
    Watch Time: 38 mins
    touchPANEL DISCUSSION
    Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice
    CE/CME ACCREDITED Dr Sarah Holstein, Dr Nikhil Munshi, Dr Noopur Raje

    Watch three specialists discuss patient cases and share their insights on optimization of treatment selection and sequencing in relapsed/refractory multiple myeloma (RRMM).

    Learning objectives
    Learning Objectives
    • Interpret factors that must be balanced when choosing therapy for patients with RRMM who have relapsed following 1–3 prior lines of therapy
    • Evaluate alternative treatment strategies for patients with RRMM following >3 prior lines of therapy
    • Identify optimal sequencing strategies for patients with RRMM in both early- and later-line settings
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72